Elanco Animal Health Incorporated (NYSE:ELAN) delivered strong financial performance for the second quarter of 2026, driven by robust demand across its Pet Health portfolio and expanding margins.
The momentum led management to raise its full-year growth outlook.
The pet health company reported adjusted earnings of 34 cents, beating the consensus of 27 cents.
Zenrelia And Credelio Quattro Gain Traction
Sales jumped 10% year-over-year on a reported basis (+8% on constant currency) to $1.368 billion, better than the consensus of $1.313 billion.
Growth was headlined by the Pet Health segment, which increased 12% reported to $718 million. A 9% volume uptick in Pet Health was primarily driven by strong consumer demand for Zenrelia and Credelio Quattro.
U.S. Pet Health’s 11% increase reflects strong growth inside the vet clinic, online and at retail, as well as in prescription and OTC products.
The company said Zenrellia’s momentum is driven by its strong efficacy differentiation. June was Zenrellia’s largest month yet despite new competition in the quarter, with U.S. penetration climbing to approximately 18,000 vet clinics.
The Farm Animal division posted revenue of $633 million, up 9% (+5%), propelled by demand across global ruminant products.
“Our strong second quarter performance allows us to both raise our full-year outlook and continue to invest in our innovation products, driving market share gains while expanding the total animal health industry,” said Bob VanHimbergen, Executive Vice President and CFO of Elanco.
“Our faster-than-expected margin expansion includes good early progress on our Elanco Ascend productivity initiatives, on track to $200 million to $250 million in adjusted EBITDA net savings by 2030. With a net leverage ratio of 3.1x at quarter-end, also faster than expected, we are closing in on our target of reaching below 3x next year, a key milestone that will unlock greater capital allocation flexibility,” VanHimbergen further commented.
In an earnings conference call, the company said, “The durable pet health market is growing, and the pet owner is simply shifting behaviors, like in most consumer markets.”
Lifts 2026 Sales and Earnings Guidance
Elanco raised its fiscal 2026 adjusted earnings guidance from $1.03-$1.09 per share to $1.10-$1.16, compared to the consensus of $1.09.
The company also raised its 2026 sales guidance from $5.01 billion-$5.085 billion to $5.09 billion-$5.14 billion, compared to the consensus of $5.062 billion. Its anticipated innovation contribution for 2026 is expected to increase by another $50 million to approximately $1.25 billion, reflecting many large products growing and gaining share in key growing global markets.
“We now have even higher confidence behind the five to six blockbuster potential innovations expected through 2031,” the company said.
For the third quarter, Elanco forecasts adjusted earnings of 19-22 cents per share versus consensus of 20 cents.
It sees sales of $1.195 billion-$1.22 billion compared to the consensus of $1.192 billion.
ELAN Stock Price Activity: Elanco Animal Health shares were up 2.50% at $26.24 at the time of publication on Wednesday, according to Benzinga Pro data.
Photo: Shutterstock
Login to comment